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After cell death, via apoptosis or necrosis, the uptake of dead cells by neighboring cells or 
phagocytes prevents the release of intracellular content. An array of molecules, including 
initiation molecules of the complement system, are involved in marking dead cells for 
uptake. After binding of these molecules, complement activation takes place, which when 
uncontrolled might result in a proinflammatory state. In the current study we demonstrate 
that complement inhibitor, C4b-binding protein (C4BP), binds strongly to necrotic cells, 
irrespective of the cell type used or the method of induction. After binding of the C4BP–
protein S (PS) complex to necrotic cells via PS-phosphatidylserine and C4BP-DNA 
interactions, C4BP-PS inhibits complement activation on these cells. C4BP binds DNA via a 
patch of positively charged amino acids, mainly on the second complement control domain 
of the C4BP 
 
 
 
-chain (affinity constant: 190 nM). Furthermore, C4BP limits DNA release 
from necrotic cells and inhibits DNA-mediated complement activation in solution. The 
C4BP–necrotic cell interaction also occurs in vivo as necrotic areas of arteriosclerotic 
plaques and of various cancers stain strongly positive for C4BP. This study describes a novel 
mechanism in which C4BP limits the inflammatory potential of necrotic cells.
 
Under physiologic conditions cell death is a
tightly regulated process in which apoptotic
cells are cleared rapidly by neighboring cells or
professional phagocytes (1–3). Nonphysiologic
cell death, necrosis, can be the result of a primary
stress signal or occur secondary to apoptosis (1).
Dead cells need to be taken up rapidly to pre-
vent the release of intracellular content and the
onset of autoimmune diseases, such as systemic
lupus erythematosus (4). Fast removal of dead
cells is dictated by a vast array of molecules
that are derived from the dying cell or from
plasma, and collectively, often are referred to
as “eat me” signals (5). Several of these proteins
that mark cells for uptake are complement com-
ponents, such as C1q and mannose-binding
lectin (MBL) (6). In addition to serving as
prophagocytic factors they also activate the
complement system (7).
Complement activation via C1q and MBL
bound to dead cells may be beneficial up to
the level of C3b because it allows interaction
with complement receptors that are present on
phagocytes, and thereby enhance phagocytosis.
However, complement activation should not
proceed beyond C3b because this would gener-
ate the anaphylatoxin, C5a, that evokes a local
inflammatory response, and leads to the forma-
tion of the membrane attack complex (C5b-9)
that induces lysis and releases intracellular con-
tents that could serve as autoantigens. Only
late apoptotic cells, and especially necrotic
cells, bind C1q and MBL (8–10); this led us to
hypothesize that a strong complement inhibitor
should be present on necrotic cells to prevent
further complement activation.
DNA is one of the autoantigens that is re-
leased from apoptotic cells, and in larger quanti-
ties from necrotic cells (11). In addition, DNA
release from granulocytes (12) is a recently de-
scribed mechanism that contributes to the plasma
DNA pool and even is present in healthy indi-
viduals. High concentrations of extracellular
DNA can be found in several clinical situations,
such as the inflamed synovium in rheumatoid
arthritis (13), and in bronchial lavage fluid of
patients who have cystic fibrosis (14). Initially,
it was reported that autologous DNA may not
be immunogenic and dangerous as such
(15); however, recent studies suggest that free
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Figure 1. C4BP binds to necrotic cells.
 
 (A) Live, apoptotic, and ne-
crotic Jurkat T cells were analyzed by flow cytometry. Shown are forward 
scatter (FSC) and side scatter (SSC) as well as stainings to discriminate live, 
apoptotic, and necrotic cells using Annexin V and ViaProbe. For live cells 
double-negative cells were gated; for apoptotic cells Annexin V–positive, 
ViaProbe-negative cells were gated; and for necrotic cells double-positive 
cells were gated. Specific binding of C4BP-FITC to these cell populations 
was compared with the binding of the negative control FITC conjugated 
mAb 104 (anti-C4BP). (B) The binding of C4BP to necrotic cells is indepen-
dent of the cell type used and the method to induce necrosis. Jurkat T cells 
were compared with Ramos B cells and monocytic THP-1 cells. Live cells 
were compared with cells induced into necrosis by heat, freeze/thaw cycles, 
or ethanol. The experiment was performed in triplicate and repeated twice; 
means and standard deviations of the mean fluorescence intensity are 
shown. (C) C4BP binding to necrotic cells in the presence of blocking mAb 
against the C4BP 
 
 
 
-chain or PS. (D) C4BP binding to necrotic cells in the  
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DNA, also mammalian (16), and especially DNA–protein
complexes are able to activate cells (17, 18). DNA is poten-
tially dangerous because it can activate complement (19, 20),
activate cells (21), and serve as a target of autoantibodies
(22); however, because DNA is present in plasma of healthy
individuals, some molecules of the immune system appar-
ently limit its proinflammatory potential.
We have hypothesized that C4b-binding protein (C4BP)
may be one of those molecules. C4BP is a key complement
inhibitory molecule for the classic and lectin pathways of
complement (23), and is present in plasma at a concentration
of 
 
 
 
200 
 
 
 
g/ml. This multidomain molecule consists mostly
of six or seven 
 
 
 
-chains and one 
 
 
 
-chain to which vitamin
K dependent anticoagulant protein S (PS) is bound with
high affinity (23). The C4BP 
 
 
 
-chain is built up almost ex-
clusively of eight complement control protein (CCP) do-
mains, and the C4BP 
 
 
 
-chain consists of three such CCP
modules. PS has the capacity to interact with negatively
charged phospholipids via its 
 
 
 
-carboxyglutamic acid do-
main. We showed previously that C4BP binds to the surface
of apoptotic cells via PS (24, 25).
Serum amyloid–P component (SAP) initially was re-
ported to be the only serum component to bind to DNA
under physiologic conditions (26). However, in the same
period, one report described the use of DNA-cellulose col-
umns to purify several proteins from serum; one of these
proteins was reported to be C4BP (27). Since then, several
complement components have been identified to bind to
DNA, such as C1q (28) and MBL (29), but some functional
importance only has been described for C1q (30).
We have argued that complement recognition of DNA
by C1q and MBL would be beneficial but that release of
proinflammatory mediators should be prevented; therefore,
we tested the complement inhibitory role of C4BP binding
to DNA in detail. Because necrotic cells are a major source
of DNA in vivo, we tested the binding of C4BP to necrotic
cells in relation to DNA release, complement activation, and
TNF-
 
 
 
 release by macrophages.
Here we demonstrate that complement inhibitor, C4BP,
binds to necrotic cells via DNA and phosphatidylserine, and
that C4BP regulates complement activation on those cells.
In addition, C4BP limits the release of DNA from necrotic
cells by binding to DNA via a positively charged patch,
mainly on CCP2 of its 
 
 
 
-chain.
 
RESULTS
The C4BP–PS complex binds strongly to necrotic cells
 
Because necrotic cells are a possible source of autoantigens
and have the potential to activate the complement system, we
tested the effect of fluid-phase complement regulator C4BP
on these processes. First we analyzed the binding of C4BP to
live, apoptotic, and necrotic cells. C4BP-PS does not bind to
live Jurkat T cells but binds strongly to apoptotic (24) and ne-
crotic Jurkat T cells (Fig. 1 A). The distribution of C4BP-PS
binding to apoptotic cells is more variable than that on ne-
crotic cells, which show strong uniform binding. To rule out
that factors specific for the cell-type or the method of induc-
ing necrosis influenced this analysis, we tested C4BP-PS
binding to three different cell lines using three different
methods of inducing necrosis. We observed no significant
binding of C4BP-PS to live Jurkat T cells, Ramos B cells, or
monocytic THP-1 cells. Upon induction of necrosis with all
three methods (heat, freeze-thawing, ethanol), we observed a
strong binding of C4BP-PS to all three cell types (Fig. 1 B).
Next we wanted to determine the mode of interaction
between necrotic cells and the C4BP-PS complex, which is
composed of several subunits. C4BP-PS-FITC was preincu-
bated with blocking antibodies against the C4BP 
 
 
 
-chain or
against PS before administration to the necrotic cells. We ob-
served that the binding to necrotic cells was inhibited partially
by the mAb against the 
 
 
 
-chain, but was inhibited strongly by
the mAb against PS, which indicated that it binds mostly via
PS–phospholipids interactions (Fig. 1 C). Necrotic cells have
been reported to be a source of DNA; therefore, we tested if
the binding of C4BP to necrotic cells could be influenced by
preincubating C4BP with exogenous DNA. Increasing con-
centrations of exogenous DNA inhibited the binding of
C4BP to necrotic cells only partially (Fig. 1 D), and to a simi-
lar extent as the blocking mAb against the 
 
 
 
-chain (Fig. 1 C).
To have a visual impression of how C4BP binds to necrotic
cells, we stained live and necrotic Jurkat T cells with Via-
Probe—to stain nuclei of dead cells that permit access of this
nuclear dye—and with C4BP-PS-FITC. Fig. 1 E shows that
C4BP binds strongly and evenly to the outer membrane of dead
cells only, and does not enter the cell or reach the nucleus.
 
C4BP-PS inhibits complement activation on necrotic cells
 
We wondered if this strong C4BP deposition has physiologic
consequences; therefore, we tested if bound C4BP-PS still
regulates complement activation. For this purpose we ana-
lyzed complement activation on necrotic cells using normal
human serum (NHS), C4BP-deficient serum, or C4BP-defi-
cient serum reconstituted with physiologic concentrations of
C4BP-PS. It is known that apoptotic cells activate some com-
plement, but it is mostly the necrotic cells that bind C1q and
MBL and activate complement strongly. Comparing NHS
with C4BP-deficient serum on necrotic cells shows that al-
though both sera deposit equal quantities of the classic path-
way initiation molecule, C1q, the C4BP-deficient serum in-
duces much more C3b deposition (Fig. 2), which indicates
that C4BP regulates the amount of C3b that is deposited on
necrotic cells. Reconstituting with C4BP-PS in the fluid-
 
presence of an increasing concentration of DNA. (E) C4BP localizes to the 
outer membrane of necrotic cells. Live and necrotic Jurkat T cells were 
incubated with C4BP FITC and ViaProbe. Using different filters for FITC, 
ViaProbe, and phase contrast, pictures were obtained from cells loaded 
onto object slides. Original magnification, 400. 
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phase fully reversed this effect. To ascertain that this actually is
due to C4BP-PS bound to the necrotic cells, we preincubated
necrotic cells at physiologic concentration of C4BP-PS and
subsequently washed and incubated with C4BP-deficient se-
rum. C3b deposition was similar to the NHS condition,
which indicates that C4BP-PS on the necrotic cell regulates
complement activation on these cells. By regulating the
amount of C3b, it also regulates the amount of C5b-9 on the
cells and C5a release (Fig. 2), and by doing so, C4BP dampens
the formation and release of these proinflammatory proteins.
 
C4BP is present on necrotic cells in clinically relevant 
necrotic lesions
 
To verify that the binding of C4BP to necrotic cells is
(patho) physiologically relevant, we tested several clinically
important conditions for the presence of C4BP on necrotic
cells. For this purpose we selected sections of two different
types of cancer and sections of human atherosclerotic plaques
that were known, from pathology reports, to contain ne-
crotic areas. We stained sections of five cases of renal cell
carcinoma, five cases of ductal carcinoma in situ of the
breast, and tissue from two patients who had carotid athero-
sclerotic plaques. All patients displayed a strong deposition of
C4BP in the necrotic areas but not in nonnecrotic tissue
around these lesions. There was some variation in the inten-
sity of staining for C4BP; representative pictures are shown
in Fig. 3. These data indicate that C4BP binding to necrotic
cells occurs in several clinically relevant conditions.
 
C4BP binds to DNA via its 
 
 
 
-chains
 
Our blocking experiments showed that binding of C4BP-PS
to necrotic cells is influenced by DNA. Therefore, we tested
the ability of complement inhibitor, C4BP, to bind to DNA
using band shift assays with Eco RI digested pcDNA3 vector
Figure 2. C4BP regulates complement activation on necrotic cells. 
Necrotic cells were incubated with NHS or C4BP-deficient serum (C4BP df) 
or C4BP-deficient serum reconstituted with C4BP in the fluid-phase (C4BP 
df   C4BP), or the necrotic cells were preincubated with purified C4BP, 
washed, and then added to the C4BP-deficient serum. Deposition of com-
plement components on the necrotic cells was analyzed by flow cytometry; 
staining for C1q, C3b, and C5b-9 is depicted as mean fluorescence intensity 
(MFI). The release of the anaphylatoxin, C5a, in the fluid phase was 
detected by ELISA and is depicted as  g/l. Mann-Whitney tests were 
performed to test for significant differences between the groups. N.S., not 
significant. *P   0.05.
Figure 3. C4BP binds to necrotic cells in vivo. Tissue sections from 
two clinically important conditions—atherosclerosis and cancer—were 
stained for the presence of C4BP on necrotic tissue. Samples from patients 
who suffered from atherosclerotic plaques, renal cell carcinoma, or ductal 
carcinoma in situ of the breast were stained with polyclonal antibodies 
against C4BP, or as a negative control by omitting the first antibody, and 
with H/E. *Location of the necrotic area in the hematoxylin-eosin–stained 
sections. Original magnification for the atherosclerotic sections was 10, 
and for the cancer samples, 100 and 400, respectively. 
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(DNA) as a target. After incubating an increasing concentra-
tion of C4BP-PS with linearized DNA, we observed a dose-
dependent retention of DNA as a high molecular weight
complex, which indicated that C4BP-PS had bound DNA
(Fig. 4 A). As a negative control we used prothrombin, an-
other plasma protein, which like C4BP-PS is known to bind
to apoptotic cells (31), and incubated a similar concentration
range with the DNA but did not observe any high molecular
retention (Fig. 4 B); this indicated that prothrombin does
not bind DNA and that the binding of C4BP-PS in this assay
was specific. C4BP-PS is composed of several subunits (see
Fig. 6 A); therefore, we tested what part of this molecule is
responsible for the DNA binding. Using blocking antibodies
against the different domains of C4BP we observed that an-
tibodies against 
 
 
 
-chain blocked the interaction with DNA
completely, whereas antibodies against 
 
 
 
-chain or PS had no
effect (Fig. 4 C). To prove that the 
 
 
 
-chains are responsible
for binding, we compared plasma-derived C4BP-PS—
which consists of C4BP 
 
 
 
-chains, one 
 
 
 
-chain, and PS—
with recombinant C4BP, which consists only of 
 
 
 
-chains
and free PS. We observed equally strong DNA binding by
plasma-derived and recombinant C4BP, and no DNA bind-
ing by PS (Fig. 4 D). These results confirm that C4BP binds
DNA through its 
 
 
 
-chains.
 
The C4BP-DNA interaction is ionic in nature and can be 
inhibited by free nucleotides
 
To identify the type of interaction between C4BP and
DNA, C4BP-PS was incubated with DNA in the presence
of an increasing concentration of NaCl. Increasing the ionic
strength of the buffer resulted in inhibition of the DNA-
C4BP interaction, and indicated that the interaction is ionic
in nature (Fig. 5 A). The interaction was inhibited by 50% at
600 mM NaCl. In addition, we tested if the interaction be-
tween C4BP and DNA was inhibited by free nucleotides.
The C4BP-DNA mixture was incubated in the presence of
an increasing concentration of deoxyribonucleoside triphos-
phate (dNTP) and an equimolar mixture of free nucleotides;
a dose-dependent inhibition of the interaction between lin-
ear pcDNA3 vector DNA and C4BP-PS was observed (Fig.
5 B). To test which of the nucleotides in the mixture was re-
sponsible for this inhibition, we added increasing concentra-
tions of each of the four nucleotides—A, T, C, and G—sep-
arately. Each nucleotide had a similar capacity to inhibit the
interaction of C4BP-PS with DNA (Fig. 5 C).
 
C4BP binds DNA via a positively charged cluster of amino 
acids on the interface between CCP1 and CCP2
 
Within the multidomain molecule of C4BP-PS, the 
 
 
 
-chains
are responsible for the interaction. By testing a set of recom-
binant deletion mutants in which individual domains had
been deleted (Fig. 6 A), we were able to determine that the
binding site for DNA is located on CCP2 with a small con-
Figure 4. C4BP binds to DNA via the  -chains. Linearized pcDNA3 
vector DNA was incubated with increasing concentrations of C4BP or 
prothrombin and separated on a regular agarose gel. As a DNA–protein 
complex the DNA migrates at high molecular weight, whereas free DNA 
migrates at low molecular weight. (A) Increasing concentrations of C4BP 
ranging from 0.2  M to 1.6  M result in C4BP-DNA binding. (B) Pro-
thrombin, even incubated at a 1:7  M ratio, to compensate for seven 
potential binding sites per C4BP molecule versus one in prothrombin, does 
not bind to DNA. (C) C4BP-PS was incubated with blocking antibodies to 
the  -chain,  -chain, and PS. (D) Plasma-derived C4BP-PS, recombinant 
C4BP, and free PS were compared for their ability to bind to DNA.
Figure 5. The C4BP–DNA interaction is ionic in nature and can be 
inhibited by free nucleotides. (A) C4BP-DNA interactions are inhibited 
by increasing the ionic strength of the buffer as indicated. (B) Inhibition of 
C4BP-DNA interactions by increasing concentrations of dNTPs from 4 to 
32 mM. (C) Dose-dependent inhibition of the C4BP-DNA interaction by 
individual nucleotides A, T, C, G each tested at 4 and 32 mM. 
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tribution by CCP1 (Fig. 6 B). It is known that there is a
patch of positively charged amino acids on this interface; be-
cause such a positively charged patch may be responsible for
the observed ionic interaction with negatively charged DNA,
we analyzed point mutants in which the individual positively
charged amino acids were substituted by the uncharged
amino acid, Gln. The positively charged amino acids—Arg-
39 on CCP1 and Lys-63 and Arg-66 on CCP2—are essen-
tial, whereas Arg-64 is intermediate and His-67 does not
seem to be essential (Fig. 6 C). By testing two ligands that are
known to interact with this cluster on the C4BP 
 
 
 
-chain,
C4b and heparin (32), we observed that these two ligands
Figure 6. C4BP binds to DNA via positively charged amino acids on 
the interface between CCP-1 and CCP-2. (A) Schematic overview of 
different C4BP forms used in this study. Plasma-derived C4BP mostly con-
sists of seven  -chains, one  -chain, and one molecule of PS bound with 
high affinity to the  -chain. Also, PS is built up of several domains but for 
simplicity is depicted as one unit. Recombinantly produced C4BP consists 
of six  -chains and lacks the  -chain and PS.  -chains are built up of 
eight CCP domains followed by short COOH-terminal extensions involved 
in polymerization of the whole molecule. Deletion mutants lacking indi-
vidual CCP domains are depicted as  CCP. (B) Deletion mutants lacking 
individual CCP domains were tested for their ability to bind to DNA. 
(C) Single amino acid mutants in which the positively charged amino acids 
have been replaced by a neutral amino acid were tested for their ability to 
bind DNA. Excess C4b, heparin, and prothrombin were used to compete for 
the binding site of DNA on C4BP. Top arrow in B and C indicates DNA–
protein complexes; bottom arrow indicates free DNA.
Figure 7. C4BP binds to various forms of DNA as well as to RNA. 
(A) RNA was incubated in buffer only or with C4BP and run on an agarose 
gel. (B) A DNA ladder was incubated with buffer only or with 0.8, 1.6, or 
3.2  M C4BP to analyze the preferential sizes of DNA for C4BP binding at 
these C4BP concentrations. Band sizes are indicated in bp. (C) Dot-blot 
analysis of C4BP binding to different forms of DNA and RNA. C4BP and C4b 
were dotted as positive controls. One blot was incubated with C4BP and 
one blot was incubated without C4BP, the developing procedure was similar. 
(D) Biacore analysis of the interaction of polymeric versus monomeric 
 -chains of C4BP with immobilized DNA. The concentrations of the ana-
lytes are indicated on the right side. The y-axis displays response units. 
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could compete with DNA for binding, which indicated that
they had similar/overlapping binding sites on C4BP (Fig. 6
C). As a negative control, we performed the same with pro-
thrombin, which could not compete. From this part of the
study we conclude that C4BP-PS binds DNA, and that this
interaction is ionic in nature and can be inhibited by individ-
ual nucleotides. The binding site on C4BP is located on the
interface between CCP1 and CCP2 and involves positively
charged amino acids at positions 39, 63, 64, and 66, a similar
binding site as used by C4b and heparin.
 
C4BP binds to several forms of DNA and RNA
 
Given the resemblance between DNA and RNA, we also
tested C4BP-RNA interaction and observed that RNA mi-
grates at high molecular weight after incubation with C4BP
(Fig. 7 A). However, we observed that only the higher band
of the RNA preparation was interacting with C4BP. There-
fore, we tested if there are size constraints for RNA/DNA
for the C4BP interaction by incubating a commercial DNA
ladder with buffer only or with 0.8, 1.6, or 3.2 
 
 
 
M C4BP.
This analysis shows that C4BP binds preferably to high mo-
lecular weight DNA; however, increasing the concentration
of C4BP resulted in high molecular retention of all DNA
fragments and indicated no real size cut-off for the interaction
between C4BP-PS and DNA (Fig. 7 B).
In addition to analyzing the binding site for DNA on
C4BP, we also studied the molecular requirements of DNA for
this interaction to occur. For this purpose we used dot-blots
onto which we dotted increasing concentrations of different
forms of DNA and RNA. We generated two identically dot-
ted blots, on which we dotted C4BP-PS as a positive control
and C4b, another natural ligand for C4BP-PS, as an additional
control. One blot was incubated with C4BP and the other
with buffer only; after incubation both blots were treated
equally and stained for the presence of C4BP. C4BP-PS binds
strongly to dsDNA, ssDNA, genomic DNA, RNA, linear, and
circular pcDNA3 vector (Fig. 7 C). The observed preference
of C4BP-PS to bind to higher molecular weight DNA may re-
late to the polymeric nature of C4BP. Therefore, we tested the
affinity of polymeric C4BP versus monomeric C4BP 
 
 
 
-chain
using Biacore. Biotinylated DNA was loaded onto streptavidin
chips, and the two forms of C4BP were injected at several
concentrations. Intact, multivalent C4BP binds DNA more
strongly, but monovalent 
 
 
 
-chains also have the capacity to
bind DNA (Fig. 7 D). The affinity constants for binding DNA
are 8.5 10
 
 
 
7
 
 M (k
 
a
 
 
 
 
 
 6.7 10
 
 
 
3
 
 1/Ms; k
 
d
 
 
 
 
 
 5.7 10
 
 
 
3
 
 1/s) for
monomeric 
 
 
 
-chains and 1.9 10
 
 
 
7
 
 M (k
 
a
 
 
 
 
 
 1.4 10
 
 
 
4
 
 1/Ms;
k
 
d
 
 
 
 
 
 2.6 10
 
 
 
3
 
 1/s) for polymeric C4BP 
 
 
 
-chains; this is in the
same affinity range as the affinity between C4BP and C4b (33).
As can be observed from the sensograms, the association and
the dissociation rate are affected by the multivalency of C4BP.
 
C4BP inhibits complement activation on DNA
 
DNA was shown to bind several complement initiation mole-
cules and to activate the classic pathway of the complement
system (19, 20). Knowing now that C4BP binds DNA, we
wondered if C4BP is involved in the regulation of comple-
ment activation on DNA in solution. We incubated increas-
ing concentrations of DNA with NHS or C4BP-deficient se-
rum. As a readout for this complement activation we used the
residual capacity of these sera to activate complement in a
classic pathway complement activation assay. The C4BP-defi-
cient serum had equal complement activity as did NHS in the
absence of DNA. Upon incubation with DNA, both sera be-
came dose-dependently depleted of classic pathway activity,
but the C4BP-deficient serum already was depleted at lower
DNA concentrations (Fig. 8) which indicated that C4BP lim-
its complement activation on DNA in the fluid-phase.
 
C4BP bound to necrotic cells limits DNA release
 
To test if C4BP on the necrotic cell also may be involved in
the regulation of DNA release, we analyzed the amount of
DNA released in the supernatant after induction of necrosis
in the presence or absence of C4BP-PS. We generated live
and necrotic Jurkat, Ramos, and THP-1 cells in medium
without FCS or in medium containing 100 
 
 
 
g/ml C4BP-PS,
and cultured these cells for an additional 8 h. Just after the in-
duction of necrosis and at the moment of collecting the su-
pernatant, we verified by FACS that similar amounts of ne-
crotic cells were present in the various conditions. We
observed a highly reproducible amount of necrotic cells using
heat, which was not affected by the presence of C4BP (un-
published data). The DNA concentration was determined in
cell-free supernatant. Live cells release some DNA during
culture, which is not inhibited by C4BP (Fig. 9 A). How-
ever, necrotic cells release more DNA and this release is in-
hibited by the presence of C4BP-PS (Fig. 9 A) which indi-
cates that C4BP-PS on the outer membrane of necrotic cells
captures DNA and retains it on the necrotic cell. We ob-
served that C4BP-PS preferentially binds high molecular
weight DNA; therefore, we analyzed what sizes of DNA are
released from cells rendered necrotic in the presence or ab-
Figure 8. C4BP-PS inhibits complement activation by DNA. Com-
plement activation on fluid-phase DNA was analyzed by incubating DNA 
with NHS or C4BP-deficient serum. Residual classic pathway activity was 
determined using lysis of immunoglobulin sensitized sheep erythrocytes 
as a read out. The experiment was performed in triplicate and means   SD 
are shown. 
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sence of C4BP-PS. We ran necrotic cells on a regular agarose
gel and observed that in the presence of C4BP-PS there was
only the low molecular weight DNA band, whereas in the
absence of C4BP-PS there also is a high molecular weight
band (Fig. 9 B). C4BP-PS captures the high molecular
weight DNA that is being released from necrotic cells, and
the residual DNA, as measured in the supernatant, most likely
is low molecular weight DNA. We did not observe a clear
inhibition of the release of intact nucleosomes by incubation
with C4BP and we also did not observe significant binding of
C4BP to intact chromosomes on cell smears (unpublished
data); collectively, these data indicated that C4BP may only
bind DNA when it is sufficiently free of histones.
 
C4BP limits the proinflammatory potential of necrotic cells
 
We generated THP-1–derived macrophages and analyzed the
effect of coincubating necrotic cells in the presence of heat-
inactivated NHS, NHS, C4BP-deficient serum, or reconsti-
tuted deficient serum, and as a readout we analyzed the pro-
duction of the proinflammatory cytokine, TNF-
 
 
 
. Compar-
ing heat-inactivated NHS with NHS, we observed a strong
increase in TNF-
 
 
 
 production which indicated that when
complement activation can take place, more TNF-
 
 
 
 is re-
leased (Fig. 10). Using C4BP-deficient serum we observed
increased amounts of TNF-
 
 
 
; this is reversed by reconstitut-
ing with purified C4BP (Fig. 10) and indicates that C4BP
limits the proinflammatory effects of necrotic cells and serum.
 
DISCUSSION
 
We describe the binding of a key complement inhibitor,
C4BP, to necrotic cells and DNA. By binding to necrotic
cells C4BP inhibits complement activation on those cells and
limits DNA release.
Although deficiencies have been reported for virtually all
complement proteins, including inhibitors (34–37), no com-
plete deficiency for C4BP has been described, although it has
been studied extensively (38, 39). Whether this means that
C4BP also has other functions is still a matter of debate. No
genetic deficiencies have been described for the DNA binding
proteins, SAP and C-reactive protein, either (40). SAP was
reported to bind to DNA (26) and to form complexes with
C4BP (41); in the current paper we show also that C4BP in
purified form binds DNA which strengthens the idea that
SAP and C4BP have roles in regulating DNA processing.
Noncell-associated DNA is present in plasma of healthy
individuals and in highly increased concentrations in plasma
of patients who have cancer (42), systemic lupus erythemato-
sus (43, 44), or rheumatoid arthritis (13). Such DNA can be
derived from degranulating neutrophils as a physiologic pro-
cess in innate defense (12) or from dying cells (45). Because
Figure 9. C4BP limits DNA release from necrotic cells. (A) DNA release 
by live and necrotic cells generated and cultured in medium only or 
medium containing 100  g/ml C4BP as determined using a PicoGreen 
assay on the supernatant. The experiment was performed in triplicate
four times, means and standard deviations are shown. Student’s t test was 
performed to test for significant differences between the groups. NS, not 
significant. * P   0.05, ** P   0.001, ***P   0.0001. (B) Necrotic cells were 
incubated with either buffer only or with C4BP and then loaded onto a 
regular agarose gel stained with ethidium bromide. Necrotic cells release 
DNA, and when these cells are generated in the presence of C4BP, only the 
low molecular weight band is visible.
Figure 10. C4BP limits the pro-inflammatory potential of necrotic 
cells and complement. THP-1 derived macrophages were incubated with 
necrotic cells in the presence of either heat inactivated NHS (HI NHS), 
NHS, C4BP-deficient serum (C4BP df) or reconstituted serum. After incu-
bation, TNF-  release by the macrophages was analyzed by ELISA. The 
experiment was performed four times in triplicate; (means and SEM) are 
shown. Analysis of variance with the Tukey posttest was performed to test 
for significant differences between the groups. *P   0.05; ***P   0.001.JEM VOL. 201, June 20, 2005 1945
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in many cancers the DNA that is present in plasma can be
used to identify the type of tumor by PCR technology, it
must be derived from dying tumor cells (46). All of the non-
cell-associated DNA in plasma was reported to be complexed
to proteins (47), and we are studying the relative contribution
of C4BP to the formation of such complexes. DNA can
stimulate cells via Toll-like receptors; this is well-known for
CpG motif–bearing nonmammalian DNA, but also is true for
mammalian DNA (16–18), especially via the simultaneous
triggering of different sets of receptors by DNA–protein
complexes (16–18). Because of its polymeric nature, C4BP
may be involved in cross-linking such cellular receptors. One
of the direct practical implications of our findings relates to
gene therapy. DNA delivery for gene therapy is of limited
success (48), in part because of complement activation on ei-
ther the DNA itself or the poly-L-lysine that serves as a car-
rier molecule (19). Preincubation of such complexes with
C4BP may block binding sites for complement-activating
molecules—and at the same time—inhibit complement acti-
vation, and thereby, increase the therapeutic success.
Binding of C4BP to necrotic cells is a broad phenomenon.
We showed that C4BP-PS binds strongly and specifically to
necrotic cells of three different cell lines, after induction of ne-
crosis using three different methods, and to necrotic cells that
are present in normal in vitro cultures. In addition, we ob-
served C4BP binding to necrotic cells in clinically important
conditions, such as vascular disease and cancer, in all samples
tested. Therefore, we propose that C4BP binding to apoptotic
(24) and necrotic cells is a fundamental property that may be
the main function of the C4BP-PS complex.
We showed previously that C4BP-PS binds to apoptotic
cells via PS–phosphatidylserine interactions (24). Phosphati-
dylserine also is available on necrotic cells and C4BP-PS
binds to them mainly via PS, but also via DNA on the outer
membrane of necrotic cells, not in the nucleus. Because
C4BP-PS is polymeric, several  -chains will be available to
inhibit complement activation and to capture free DNA that
is released from such cells.
Generating a C4BP-deficient mouse would seem to be
an attractive approach to confirm these data in vivo; how-
ever, murine C4BP is different from human C4BP because
it lacks the  -chain and PS (49). This may make mouse
C4BP behave differently; it probably will not bind to apop-
totic cells directly but should be able to interact with DNA.
This does not mean that the C4BP-PS system cannot be im-
portant in man, but it indicates that a murine system may not
be optimal to study the role of C4BP-PS in vivo.
Binding between C4BP and DNA is established via posi-
tively charged amino acids at the interface between CCP1 and
CCP2. A similar site also is used for binding to heparin (32),
streptococcal M-proteins (50), and C3b and C4b (23). The es-
timated affinity constant for the C4BP–DNA interactions of
the polymeric molecule versus the monomeric  -chains were
1.9 10 7 M versus 8.5 10 7 M. These numbers are in the same
range as the affinities for C4b (51). We are studying if high
concentrations of DNA can affect C4BP function.
Although necrosis generally is considered to be a more
proinflammatory condition than apoptosis, in our opinion it
is essential to realize that several factors are involved in
dampening the proinflammatory potential of necrotic cells
just as is the case with apoptotic cells. The current paper
shows that C4BP limits C3b and C5b9 deposition on ne-
crotic cells and the release of C5a and DNA. C4BP also lim-
its the proinflammatory response of macrophages induced by
necrotic cells and serum. Although necrotic cell death is un-
controlled in its death process at the level of the individual
cell, it is not unregulated by the host.
MATERIALS AND METHODS
Cells and induction of necrosis. Jurkat T cells; Ramos B cells; and the
monocytic cell line, THP-1, (all purchased from ATCC) were grown in
RPMI 1640, supplemented with glutamin, penicillin, streptomycin, and
10% heat-inactivated FCS (all from Invitrogen). Washed cells were induced
into apoptosis or necrosis. Apoptotic cells were generated by addition of 1
 M staurosporine (Sigma-Aldrich) to Jurkat T cells for 3 h. Necrosis was
induced by using three different methods: (a) heat: cells were brought to a
concentration of 106 per ml and incubated at 56 C for 30 min, (b) repeated
freeze-thaw cycles: five times freeze-thaw from  80 C to  56 C in 60
min, or (c) by incubation in 10% ethanol for 60 min at 37 C.
THP-1 cells were differentiated into macrophages at 25,000 cells per well
in a 96-well plate using 100 nM PMA (Sigma-Aldrich) in complete RPMI
1640 for 72 h in total with a change to fresh medium after 48 h. Necrotic Jur-
kat cells (heat) were used at 250,000 per well in RPMI 1640, without FCS,
containing 0.5  g/ml LPS (Escherichia coli 026:B6, Sigma-Aldrich) supple-
mented with NHS, heat-inactivated NHS, C4BP-deficient serum, or defi-
cient serum reconstituted with C4BP all at a final concentration of 20%. Cells
were coincubated for 6 h and cell-free supernatant was tested in TNF- 
ELISA (R&D Systems) following the instructions of the manufacturer.
Proteins and sera. The C4BP-PS complex was purified from human
plasma as described (52). Recombinant wild-type C4BP and different mu-
tants lacking individual CCP domains or with introduced point mutations
Arg39Gln, Lys63Gln, Arg64Gln, Arg66Gln, His67Gln, and Arg64Gln-
Arg66Gln were generated and purified as described (53, 54). PS was puri-
fied as described (52), prothrombin was purified using BaCl2 precipitation
and DEAE-Sephacel chromatography, C4 was purified, and C4b was gen-
erated as described (51). Heparin was obtained from ICN Biomedicals.
mAb 104 against the  -chain of C4BP, mAb 2B against the  -chain of
C4BP, and mAb 21 against PS were a gift of B. Dahlbäck, Lund University,
Sweden. NHS was obtained from freshly drawn blood from healthy volun-
teers that was allowed to clot for 30 min at room temperature and all further
steps on ice; individual sera were pooled and stored in aliquots at –70 C or
used to generate depleted serum. Human serum deficient in C4BP-PS was
prepared by passing fresh serum through a HiTrap column (Amersham Bio-
sciences) coupled with mAb 104 (55). The flow through was collected and
the depleted serum was stored in aliquots at –70 C. The C4BP-PS prepara-
tions did not contain any DNase I activity.
Nucleic acids. pcDNA3 plasmid DNA (Invitrogen) was linearized using
EcoRI (Fermentas). Human genomic DNA was isolated using QIAGEN
Blood Maxi kit following instructions of the manufacturer and whole blood
from a healthy volunteer. dsDNA and ssDNA from calf thymus were ob-
tained from Sigma-Aldrich. RNA was isolated using RNA-easy kit from
QIAGEN using mouse spleen as a source. The dNTPs were from Amer-
sham Biosciences.
Flow cytometry. Cell populations were analyzed using flow cytometry.
To discriminate live, apoptotic, and necrotic populations, cells were stained
with annexin V–PE (Molecular Probes) and ViaProbe (7-AAD, MolecularC4BP BINDS TO NECROTIC CELLS AND LIMITS DNA RELEASE | Trouw et al. 1946
Probes). C4BP binding was analyzed by incubating cells with 2  g of C4BP-
FITC or as a control with 2  g of mAb 104-FITC in 50  l binding buffer
(10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2)
for 30 min at room temperature. Blocking experiments were performed by
preincubating C4BP-FITC with anti– -chain mAb 104 or with anti-PS
mAb 21 at a 1  g mAb:1  g C4BP-FITC ratio or with 0.25, 1.25, or 2.5  g
dsDNA per  g C4BP-FITC at room temperature for 30 min. Complement
deposition was analyzed using rabbit anti-C1q FITC (DakoCytomation),
rabbit anti-C3 FITC (DakoCytomation), goat–anti-C9 (Advanced Research
Technologies), and rabbit anti–goat FITC (DakoCytomation).
Cell staining. Live and necrotic Jurkat T cells were stained for C4BP
binding and cell viability using C4BP-FITC and ViaProbe. Cells were in-
cubated with a combination of 1  g C4BP-FITC and 5  l ViaProbe in 25
 l binding buffer. Cells were mounted on glass slides and visualized using a
regular Olympus microscope equipped with the appropriate filters. Original
magnification was 400.
Immunohistochemistry. Sections for three conditions of clinically ob-
served necrosis were stained and permission for their use was obtained from
the relevant local ethical committees. The sections were selected by a pa-
thologist with the presence of one or more necrotic lesions as the only in-
clusion criterion, based on histologic features of necrosis. We stained sec-
tions from five cases of renal cell carcinoma and five cases of ductal
carcinoma in situ of the breast from archived formalin-fixed, paraffin-
embedded, surgical tumor specimens. In addition, we stained frozen tissue
from two patients who had carotid atherosclerosis. Sections were deparaf-
finized following standard procedures or stained directly for frozen sections.
Polyclonal rabbit anti–human C4BP was used as primary antibody at 10
 g/ml, washed and followed by goat anti–rabbit HRP, substrate and hema-
toxylin counter stain. As a negative control we stained the same sections by
omitting primary antibody.
Gel shift analyses. Binding of C4BP to DNA was evaluated using gel
shift analysis. DNA and proteins were mixed using 0.2  g linearized
pcDNA3 vector DNA with 1 to 8  g protein in a 10- l reaction volume
containing Tris EDTA buffer (10 mM Tris-HCl, 5 mM EDTA, pH 7.6)
and incubated for 30 min at 37 C. DNA–protein complexes were separated
by 0.8% agarose gel electrophoresis in 40 mM Tris acetate, pH 8, buffer and
0.5  g/ml ethidium bromide and visualized by UV transluminator. For
most consecutive studies, 0.2  g DNA and 2  g protein were incubated in
a 10- l reaction volume containing competitors in TE-buffer for 30 min at
37 C and analyzed as described. Blocking antibodies were incubated at 1  g
mAb per  g of C4BP. mAb 104 was used to block the  -chain of C4BP-
PS, mAb 2B was used to block the  -chain of C4BP-PS, and mAb 21 was
used to block PS. Plasma-derived C4BP-PS and recombinant C4BP were
compared for binding to DNA at 0.8  M; free PS was analyzed at 5  M.
To test for ionic interactions, C4BP-PS and DNA were incubated at in-
creasing concentrations of NaCl (150 mM, 300 mM, 600 mM, and 1,200
mM). To test if the interaction between C4BP-PS and DNA was depen-
dent on a particular nucleotide, mixtures of all four dNTPs or individual
nucleotides were added at 4 mM, 8 mM, 16 mM, or 32 mM. Both deletion
mutants lacking individual CCP domains or point mutants as described at
proteins and sera were analyzed at 0.8  M. Blocking the interaction be-
tween C4BP-PS and DNA was performed with 4  g C4b, 4  g heparin,
and 4  g prothrombin per 1  g C4BP-PS. RNA–C4BP–PS interactions
were visualized by performing gel-shift analysis using 0.1  g RNA and 0.8
 M C4BP-PS. To determine size dependency of the C4BP–DNA interac-
tion, 4  g of a 1-kb DNA-ladder (Fermentas) was incubated with buffer
only or with 0.8 or 3.2  M C4BP-PS and analyzed in the gel-shift assay.
Dot blot. Several forms of DNA and RNA, as described in the “nucleic
acids” section, were dotted in decreasing concentration onto Hybond-C
extra nitrocellulose membrane (Amersham Biosciences). Two identical blots
were produced dotting C4BP-PS and C4b as positive controls at 1, 0.25,
and 0.06  g per dot, and DNA/RNA samples at 0.2, 0.05 and 0.013  g
per dot in a 2- l volume. Blots were washed using wash buffer (50 mM
Tris HCl, 0.15 M NaCl, 0.1% Tween) and blocked using Quench (wash
buffer supplemented with 3% fish gelatin) for 1 h at room temperature. One
blot was incubated with 5  g/ml of C4BP-PS for 1 h at room temperature,
the other blot was incubated with buffer only. Both blots were washed
three times with washing buffer and stained for C4BP-PS using our anti-
C4BP mAb 104 and goat anti–mouse alkaline phosphatase (DakoCytoma-
tion). Blots were developed using color substrate reaction.
Surface plasmon resonance. To measure the kinetics of DNA-C4BP
interaction we coupled biotinylated DNA to a streptavidin chip (Biacore).
Double-stranded 25-mer oligonucleotides (G-C)25 and (A-T)25 were pro-
duced using equimolar amounts of single-stranded 5  biotinylated 25-mer
oligonucleotides (MWG) as described (56). Equal concentrations of G–C
and A–T were coupled to the streptavidin sensor chip surface to a level of
300 response units. All experiments were performed at a continuous flow
rate of 30  l/min using Biacore buffer (150 mM NaCl, 10 mM Hepes, 2.5
mM CaCl2, 0.002% Tween-20, pH 7.4). Analytes, C4BP intact molecule,
and C4BP monovalent  -chains were run over the chip in a concentration
gradient. The chip was regenerated using pulse injection of 3 M guanidium
chloride followed by 1 M NaCl. The obtained sensograms were analyzed
using Bio-evaluation software 3.0 using 1:1 model of interaction with drift-
ing baseline and Rmax local.
Complement activation assays. Complement activation on fluid-phase
dsDNA was analyzed by incubating increasing concentrations of dsDNA
with NHS or C4BP-deficient human serum. The mixtures of DNA and se-
rum were incubated at 37 C for 1 h. Under these conditions DNA will ac-
tivate the complement system and consume it partially. As a readout of
complement consumption, residual classic pathway activity was determined
using a hemolytic assay as described previously (55). In brief, sheep erythro-
cytes coated with antibodies were incubated with controls or serial dilutions
of sera that had been incubated previously with the DNA preparations. Re-
lease of hemoglobulin in the fluid-phase was used as a readout of comple-
ment-mediated lysis.
Analysis of complement activation and deposition on necrotic cells was
performed by flow cytometry. Cells were rendered necrotic by heat as de-
scribed in the section entitled “Cells and induction of necrosis” and washed
with DGVB   (2.5 mM veronal buffer, pH 7.3, containing 70 mM NaCl,
140 mM glucose, 0.1% gelatin, 1 mM MgCl2 and 0.15 mM CaCl2) and
transferred to 96-well plates (Greiner) at 105 cells in a 50- l volume con-
taining DGVB   and 10% NHS, C4BP-deficient human serum, or C4BP-
deficient serum reconstituted with physiologic concentrations of C4BP-PS.
Samples were incubated on a shaker for 30 min at 37 C. Deposition of C1q,
C3, and C5b-9 was analyzed as described in the section entitled “Flow cy-
tometry.” C5a-release in the fluid phase was determined in the supernatant
using a C5a detection kit (IBL) according to the instructions of the manu-
facturer. Assays were performed twice in triplicate.
DNA-release assay.  Jurkat T cells, Ramos B cells, and THP-1 cells were
kept alive or made necrotic as described in the Cells and induction of ne-
crosis section in RPMI 1640 without FCS in the presence or absence of
100  g/ml C4BP-PS. Cells were plated at 105 cells in 100  l and cultured
for an additional 8 h. Cells were analyzed just before and after the experi-
ment by flow cytometry for the percentage of live, apoptotic, and necrotic
cells by staining with Annexin V and ViaProbe as described in the Flow cy-
tometry section. Cells and supernatant were separated by centrifugation in
V-bottom plates and the DNA content of the supernatant was analyzed us-
ing a PicoGreen DNA quantification kit (Molecular Probes) as described by
the manufacturer. Experiments were performed in triplicate and repeated
four times. Averages and standard deviations are shown.
Statistical analysis. We used Mann-Whitney, Student’s t and ANOVA
with Tukey posttest, to test for significant differences between groups.JEM VOL. 201, June 20, 2005 1947
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